Characteristics and course of heart failure stages A-B and determinants of progression - The STAAB cohort study

Characteristics and course of heart failure stages A-B and determinants of progression - The STAAB cohort study - STAAB

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00011715

Enrollment

5000

Registered

2017-08-02

Start date

2013-12-12

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I50

Interventions

Group 1: In a randomized sample of residents of Würzburg, the following investigations are carried out: • cardiac and vascular diagnostics (resting ECG, echocardiography, measurement of blood pressure

Eligibility

Sex/Gender

All

Age

30 Years to 79 Years

Inclusion criteria

Inclusion criteria: men/women aged 30-79 years who are citizens of the city of Wurzburg

Exclusion criteria

Exclusion criteria: Previously diagnosed heart failure (stages C and D)

Design outcomes

Primary

Measure	Time frame
Major endpoint is the presence of heartfailure ("no" or stage A/B/C/D as per AHA/ACC classification) at the respective time of examination. Endpoints subordinate to the main endpoint are all characteristics that contribute to the qualification for the individual stages of heart failure: • risk factors (especially obesity, hypertension, hyperlipidemia, diabetes mellitus, chronic renal insufficiency); Defined by pre-existing diagnosis, existing treatment for this reason or currently collected measured values ??(if applicable). The limits ??for the measured targets ??are defined by the guidelines at the beginning of the analysis; They are specified in the analysis plan. • Characteristics of structural heart failure: CHD (defined by preexisting diagnosis or revascularisation or myocardial infarction), echocardiographic measurements (impaired systolic or diastolic function, dilatation, hypertrophy, valve vortices,targets according to guidelines at start of analysis), ECG (positive Sokolov index, Index) • Symptoms and signs of heart failure If individual characteristics are considered controversial, primary and other secondary variants of the main end point can be defined and the calculations can be executed several times. Data are collected both during initial and follow-up investigations (Data from face-to face-interviews and physical examinations)	—

Measure

Time frame

Major endpoint is the presence of heartfailure ("no" or stage A/B/C/D as per AHA/ACC classification) at the respective time of examination. Endpoints subordinate to the main endpoint are all characteristics that contribute to the qualification for the individual stages of heart failure: • risk factors (especially obesity, hypertension, hyperlipidemia, diabetes mellitus, chronic renal insufficiency); Defined by pre-existing diagnosis, existing treatment for this reason or currently collected measured values ??(if applicable). The limits ??for the measured targets ??are defined by the guidelines at the beginning of the analysis; They are specified in the analysis plan. • Characteristics of structural heart failure: CHD (defined by preexisting diagnosis or revascularisation or myocardial infarction), echocardiographic measurements (impaired systolic or diastolic function, dilatation, hypertrophy, valve vortices,targets according to guidelines at start of analysis), ECG (positive Sokolov index, Index) • Symptoms and signs of heart failure If individual characteristics are considered controversial, primary and other secondary variants of the main end point can be defined and the calculations can be executed several times. Data are collected both during initial and follow-up investigations (Data from face-to face-interviews and physical examinations)

—

Secondary

Measure	Time frame
Secondary endpoints: there are numerous pre-planned module-specific outcomes, including for example identification of risk factors, intermediate (preclinical) phenotypes, and comorbidities on changes in cardiac function	—

Countries

Germany

Contacts

Public ContactTheresa Tiffe

Institut für Klinische Epidemiologie und Biometrie der Universität Würzburg

tiffe_t@ukw.de0931 / 201 247303

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 9, 2026